The Europe Autoimmune Disease Diagnostic Market for the period 2015-2020 is expected to account for USD XX billion at a CAGR of XX% from USD XX billion on 2015. Autoimmune diseases are a group of diseases characterized by inflammatory reactions caused by immune responses mistakenly generated against body tissues.
The term autoimmune disease refers to a varied group of illnesses that involve almost every human organ system. Environmental, infectious, and genetic factors play an important role in initiating or exacerbating autoimmune diseases.
The European Autoimmune Disease Market is driven by various factors like growing public awareness about the disease condition, improvement in laboratory automations, increasing partnerships between physicians and clinical laboratories and technological innovations. However, the market is restrained by the slow turnaround time for autoimmune disease diagnostic test result and the high frequency of false positive results.
The European autoimmune disease diagnostic market is basically segmented based on disease type and diagnostics. Based on disease type the market is further segmented as systemic autoimmune disease (rheumatoid arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus) and localized autoimmune disease (Inflammatory bowel syndrome, Type 1 diabetes, thyroid and others). Based on diagnostics, the market is segmented as Immunofluorescence assays, enzyme linked immnosorbent assay, western blotting, dot blot, line blot, multiplex immunoassay, agglutination, double immune diffusion and counterimmuno electrophoresis.
Based on geographical location, the Europe autoimmune disease diagnostic market can be broadly divided into France, UK, Germany, Spain, Portugal, Scandinavia and Italy.
European Union funded research projects like PRECISESADS and the high prevalence of the disease in Europe are some of the market opportunities for the market players. However, they face the challenge to deal with a shortage of skilled personnel who can operate the technology. The key players are F.Hoffmann-La Roche, Novartis AG, Pfizer Inc., Eli Lilly among many others.
Key Deliverables in the Study